Rafael Moreno

10PUBLICATIONS
66CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 08, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy.

|Feb 17, 2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.

Xavier Garcia-Del-Muro, Begoña P Valderrama, Ana Medina-Colmenero

|Jan 05, 2024
Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors.

M Costa-Garcia, J J Rojas, M D Ramos

|Jul 14, 2023
SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy.

Juan José Soto-Castillo, Lucía Llavata-Marti, Roser Fort-Culillas

|Jul 26, 2020
Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral Fitness.

Martí Farrera-Sal, Jana de Sostoa, Estela Nuñez-Manchón

|Jun 18, 2019
Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers.

Paula Barlabé, Jana de Sostoa, Carlos Alberto Fajardo

Pageof 2

Frequent Collaborators

5 joint publications

Ramon Alemany

3 joint publications

Miriam Bazan-Peregrino

2 joint publications

Javier García-Castro

2 joint publications

Marcel Costa-García